EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Type B insulin resistance syndrome coexisting with aplastic anemia responsive to early immunosuppressive therapy

Taro Fujisawa iD, Kazuhisa Takami iD, Mariko Horikawa, Masahiro Yokoyama, Tomoya Kawashima, Akiyoshi Takami iD

JCEM Case Reports · 02.07.2026 · 4 (8)

DOI: 10.1210/jcemcr/luag181 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 13.07.2026. Verfasst von Taro Fujisawa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism/Diabetes Center, Central Japan International Medical Center, Minokamo 505-8510, Japan. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type B insulin resistance syndrome (IRS) is a rare autoimmune disorder characterized by severe insulin resistance caused by autoantibodies against the insulin receptor. Clinically, it presents with fluctuating hyperglycemia and hypoglycemia and is frequently associated with other autoimmune diseases. We report a case with the rarely reported combination of type B IRS and aplastic anemia. A 77-year-old woman with obesity presented with abrupt deterioration of glycemic control and bilateral lower extremity edema. Despite the administration of up to 300 units/day of insulin after hospitalization, hyperglycemia remained refractory. Markedly elevated insulin receptor autoantibody titers (85.9%) confirmed the diagnosis of type B IRS. Further evaluation for concomitant pancytopenia revealed aplastic anemia on bone marrow examination. Immunosuppressive therapy with cyclosporine and eltrombopag for aplastic anemia improved the hyperglycemia; however, early morning hypoglycemia, renal dysfunction associated with intravascular volume depletion, and persistent lower extremity edema remained unresolved. The addition of glucocorticoid therapy resulted in rapid clinical improvement and marked reduction in the insulin receptor autoantibody titers (8.6%). This case highlights the importance of early and appropriate immunomodulatory therapy to achieve remission in type B IRS, particularly in patients with multiple concomitant autoimmune diseases.

Schlagwörter

Stichwörter der Autor:innen

aplastic anemiaautoimmune diseaseimmunosuppressive therapyinsulin receptor autoantibodytype B insulin resistance syndrome

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism/Diabetes Center, Central Japan International Medical Center, Minokamo 505-8510, Japan.
  • Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.
  • Department of Internal Medicine, Division of Hematology, Aichi Medical University School of Medicine, Nagakute, Aichi 480-1195, Japan.

ORCID-Profile: Taro Fujisawa, Kazuhisa Takami, Akiyoshi Takami

Zitieren

APA

Fujisawa, T., Takami, K., Horikawa, M., Yokoyama, M., Kawashima, T., & Takami, A. (2026). Type B insulin resistance syndrome coexisting with aplastic anemia responsive to early immunosuppressive therapy. JCEM Case Reports, 4(8). https://doi.org/10.1210/jcemcr/luag181

Vancouver

Fujisawa T, Takami K, Horikawa M, Yokoyama M, Kawashima T, Takami A. Type B insulin resistance syndrome coexisting with aplastic anemia responsive to early immunosuppressive therapy. JCEM Case Reports. 2026;4(8). doi:10.1210/jcemcr/luag181

BibTeX
@article{Fujisawa2026,
  author = {Fujisawa, Taro and Takami, Kazuhisa and Horikawa, Mariko and Yokoyama, Masahiro and Kawashima, Tomoya and Takami, Akiyoshi},
  title = {Type B insulin resistance syndrome coexisting with aplastic anemia responsive to early immunosuppressive therapy},
  journal = {JCEM Case Reports},
  year = {2026},
  volume = {4},
  number = {8},
  doi = {10.1210/jcemcr/luag181}
}
Kostenlos starten →